Time Release Arginine elevates the plasma level of L-arginine, a “semi-essential” amino acid considered the most potent nutraceutical ever discovered. It is perhaps the only nutraceutical whose remarkable properties are validated by a Nobel Prize in Medicine (1998). More than 60,000 clinical studies have brought L- arginine to the forefront of modern medicine as a nutrient that offers a wide range of health benefits.
As the substrate of nitric oxide-generating enzymes (NO synthetases), L-arginine is considered a direct nitric oxide (NO) precursor. Nitric oxide is an endogenously produced cellular signaling molecule involved in a variety of endothelium-mediated effects in the vasculature. The plasma concentration of L- arginine might be a rate-limiting factor for NO production. Oral supplementation with L-arginine has been demonstrated in humans to increase smooth muscle relaxation, inhibit platelet aggregation, and inhibit expression of adhesion molecules and endolelin-1. L-arginine drives the biosynthesis of NO in tissues including the vascular endothelium and skeletal muscle. Acting via the cGMP intracellular signaling system, NO increases blood flow without increasing blood pressure. In short, NO causes vasodilation by inhibiting smooth muscle contraction. Increased blood flow results in increased nutrient uptake and glucose utilization into muscle, especially during exercise.
In addition to the cardiovascular/circulatory benefits, L-arginine is involved in ammonia detoxification, hormone secretion and immune health. It supports the synthesis of protein. The generation of nitric oxide may act as a molecular switch that activates PGC-1α, the master
regulator of mitochondrial biogenesis and energy metabolism. Many athletes have safely and effectively used it to increase ‘muscle pump’ during and for several hours after a workout, increase overall workout capacity (muscular endurance), and increase post-exercise recovery.
ACTINOS® is a mixture of both high and low molecular weight fractions of proteins and peptides derived from whey through patent-pending technology. Strong evidence suggests that these fractions are NOS activators that boost NO production by factors unrelated to arginine, Ca++, or bradykinin. ACTINOS possibly increases the transcription of NOS gene and its role in reducing the negative feedback mechanism on NO production. The synergistic activity of the size-based fractions of ACTINOS has been shown to increase NO production in human endothelial cells in vitro from 9.5 to 12.7 times compared to a control.
Time Release Arginine is manufactured in the U.S. using the highest purity commercially-available (>98.0%) L-arginine alpha-ketoglutarate. This patented formulation is specially designed to deliver L-arginine alpha-ketoglutarate in a controlled manner over a period of about 4-6 hours. A considerable fraction of an oral L-arginine dose is metabolized pre-systemically or excreted from the gut; then eliminated by glomerular filtration and almost completely reabsorbed by the renal tubules.
‡ Results confirmed in in-vitro studies. ACTINOS® is a registered trademark of Glanbia plc.
1. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol. 2006;(176 Pt 1):213-54 [PMID: 16999221]
2. Tousoulis D, et al.Mechanisms of disease: L-arginine in coronary atherosclerosis–a clinical perspective. Nat Clin Pract Cardiovasc Med. 2007 May;4(5):274-83. [PMID: 17457351]
3. Boger,RH, Bode-Boger,SM: The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol 41:79-99, 2001 [PMID: 11264451]
4. Preli,RB, Klein,KP, Herrington,DM: Vascular effects of dietary L-arginine supplementation. Atherosclerosis 162:1-15, 2002 [PMID: 11947892]
5. Nisoli E, et al. Effects of nitric oxide on proliferation and differentiation of rat brown adipocytes in primary cultures. Br J Pharmacol. 1998 Oct;125(4):888-94 [PMID: 9831929]
6. Nisoli E, Carruba MO. Nitric oxide and mitochondrial biogenesis. J Cell Sci. 2006; 119:2855-2862 [PMID: 16825426]
7. Rassaf T, et al. Nitric oxide synthase-derived plasma nitrite predicts exercise capacity. Br J Sports Med. 2007 Oct;41(10):669-73; [PMID: 17496072]
8. Inhouse report. Glanbia Nutritionals Inc., 2006 CFMN-CSR-0506-1
9. Tangphao O, et al. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. Br J Clin Pharmacol. 1999 Mar;47(3):261-6 [PMID: 10215749]
The information contained in this paper has not been evaluated by the FDA. The associated product is not intended to diagnose, treat, cure, or prevent any disease.